Skip to main content
Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
753.41
+23.68 (3.25%)
At close: Nov 20, 2024, 4:00 PM
750.24
-3.17 (-0.42%)
Pre-market: Nov 21, 2024, 4:12 AM EST

Eli Lilly Revenue by Segment
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Diabetes
26.16B 23.47B 20.97B 19.67B 17.90B 16.84B 15.27B 14.46B
Diabetes Growth
46.17% 39.40% 37.36% 35.97% 26.78% 22.67% 13.38% 9.68%
Oncology
8.08B 7.60B 7.11B 6.66B 6.43B 5.97B 5.67B 5.67B
Oncology Growth
25.83% 27.27% 25.46% 17.51% 18.46% 7.85% -0.92% -1.31%
Immunology
4.21B 4.01B 3.85B 3.80B 3.63B 3.51B 3.37B 3.34B
Immunology Growth
15.98% 14.30% 14.21% 13.54% 7.70% 0.01% -3.45% -0.48%
Neuroscience
1.44B 2.86B 2.91B 2.88B 2.90B 1.51B 1.51B 1.55B
Neuroscience Growth
-50.26% 89.84% 92.66% 86.18% 77.83% -11.84% -17.58% -18.56%
Other
968.50M 981.80M 1.09B 1.12B 1.22B 1.69B 1.87B 3.52B
Other Growth
-20.74% -41.97% -41.83% -68.12% -74.00% -63.16% -61.08% -14.78%

Revenue by Geography
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
US
27.80B 25.35B 23.05B 21.79B 19.99B 19.05B 17.45B 18.19B
US Growth
39.03% 33.10% 32.07% 19.80% 6.88% 4.23% -3.28% 8.20%
Europe
5.81B 6.75B 6.52B 6.17B 5.91B 4.40B 4.32B 4.30B
Europe Growth
-1.71% 53.44% 50.93% 43.62% 35.21% -0.34% -4.42% -10.00%
Rest of World
3.95B 3.62B 3.17B 2.95B 3.02B 2.88B 2.77B 2.85B
Rest of World Growth
30.64% 25.97% 14.14% 3.30% 8.23% 0.86% -2.49% 5.55%
Japan
1.69B 1.66B 1.65B 1.67B 1.63B 1.73B 1.72B 1.75B
Japan Growth
4.06% -4.00% -4.35% -4.28% -13.70% -13.48% -21.81% -26.18%
China
1.61B 1.54B 1.54B 1.54B 1.51B 1.47B 1.42B 1.45B
China Growth
6.28% 5.01% 8.75% 5.98% 2.35% -4.53% -16.81% -12.56%

Operating Expense Breakdown
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Research and Development
10.53B 10.21B 9.85B 9.31B 8.75B 8.14B 7.57B 7.19B
Research and Development Growth
20.40% 25.37% 30.21% 29.52% 22.26% 15.30% 8.84% 2.35%
Marketing, Selling, and Administrative
8.09B 7.80B 7.61B 7.40B 7.12B 6.93B 6.63B 6.44B
Marketing, Selling, and Administrative Growth
13.65% 12.49% 14.69% 14.95% 11.46% 9.12% 3.40% 0.14%
Acquired In-Process Research and Development
3.71B 3.86B 3.81B 3.80B 3.42B 504.60M 847.90M 908.50M
Acquired In-Process Research and Development Growth
8.68% 665.46% 348.79% 318.25% 208.95% -58.68% 2.94% -6.35%
Impairment, Restructuring, and Other
523.37M 441.77M - 6.77M - - - 244.60M
Impairment, Restructuring, and Other Growth
- - - -97.23% - - - -22.62%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.